S. Nicholls

Publications889
h-index80
Citations33,758
Highly Influential Citations948
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • S. Nissen
  • 810 Publications • 63,040 Citations
  • C. Ballantyne
  • 1,594 Publications • 86,964 Citations
  • P. Libby
  • 1,260 Publications • 189,335 Citations
  • P. Barter
  • 635 Publications • 52,170 Citations
  • Publications
  • Influence
Low-density lipoproteins cause atherosclerotic cardiovascular disease
Ference, Brian A.; Ginsberg, Henry N.; Graham, Ian; Ray, Kausik K.; Packard, Chris J.; Bruckert, Eric; Hegele, Robert A.; Krauss, Ronald M.; Raal, Frederick J.; Schunkert, Heribert; Watt, Gerald F.;…
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
TLDR
Those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes.
View on PubMed
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
View on PubMed
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
TLDR
In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events.
View on PubMed
Protein carbamylation links inflammation, smoking, uremia and atherogenesis
TLDR
The discovery of an alternative and quantitatively dominant mechanism for cyanate formation and protein carbamylation at sites of inflammation and atherosclerotic plaque is reported: myeloperoxidase-catalyzed oxidation of thiocyanate, an anion abundant in blood whose levels are elevated in smokers.
View on Nature
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
TLDR
Pioglitazone is associated with a significantly lower risk of death, myocardial infarction, or stroke among a diverse population of patients with diabetes and is homogeneous across trials of different durations, for different comparators, and for patients with or without established vascular disease.
View on PubMed
Antiinflammatory Properties of HDL
There are several well-documented functions of high-density lipoprotein (HDL) that may explain the ability of these lipoproteins to protect against atherosclerosis. The best recognized of these is…
View on Wolters Kluwer
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
TLDR
In patients with type 2 diabetes and coronary artery disease, treatment with pioglitazone resulted in a significantly lower rate of progression of coronary atherosclerosis compared with glimepiride.
View on PubMed
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.
TLDR
This study provides direct evidence for a mechanistic link between genetic determinants and activity of Pon1 with systemic oxidative stress and prospective cardiovascular risk, indicating a potential mechanism for the atheroprotective function of PON1.
View on PubMed
Effect of torcetrapib on the progression of coronary atherosclerosis.
TLDR
The CETP inhibitor torcetrapib was associated with a substantial increase in HDL cholesterol and decrease in LDL cholesterol and was also associated with an increase in blood pressure, and there was no significant decrease in the progression of coronary atherosclerosis.
View on PubMed
...
...